3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

139.66 +0.26 ( +0.19% ) 4:02 2/14/20 Pricing delayed 20 minutes

Volume 164,939

Recent News

See All
February 3, 2020 ­Nevro to Report Fourth Quarter and Full Year 2019 Financial Results
Company to Host Conference Call on Tuesday, February 25, 2020 at 1:30 p.m. PT / 4:30 p.m. ET  Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on February 25, 2020. Investors interested in listening to the conference call may do so by dialing (833) 286-5807 in the U.S. or (647) 689-4452 internationally, using Conference ID: 1864387.  In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: www.nevro.com. About Nevro Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and...
January 22, 2020 Nevro to Present New Clinical Evidence at the 23rd Annual North American Neuromodulation (NANS) Society Meeting
Company Presentations Highlight Unique Applications and Increased Versatility of HF10 Therapy  Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the Company's HF10™ therapy for patients with chronic pain.  Results will be presented at the North American Neuromodulation Society (NANS) meeting held in Las Vegas, January 24-26, 2020. This year a total of 25 presentations on Nevro's clinical research, consisting of 11 podium presentations and 14 poster abstracts, will be presented at NANS 2020.  The broad range of research investigates both new and established pain areas, programming versatility with paired waveforms, and preclinical studies to understand the unique mechanism of action with HF10 therapy. Dr. Erika Petersen, Director of Functional and Restorative Neurosurgery at UAMS, and lead Principal Investigator for the...
January 20, 2020 Nevro Names Donald A. Middlebrook to Lead Clinical, Regulatory and Quality
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Donald A. Middlebrook has been named Vice President, Clinical, Regulatory and Quality, reporting directly to Chairman, CEO and President D. Keith Grossman.  Mr. Middlebrook brings to Nevro more than 30 years of senior leadership experience in regulatory affairs, clinical affairs and quality assurance in the medical device industry. "We're pleased to have a leader of Don's caliber join Nevro to advance our clinical pipeline and oversee our global regulatory and quality initiatives," said D. Keith Grossman, Chairman, CEO and President of Nevro.  "As a combined organization under Don's leadership, we are improving our efficiency and continuing our commitment to maintaining the highest levels of clinical, regulatory and quality compliance throughout our organization." In his most recent experience, Mr. Middlebrook served...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, Senza II, Senza Omnia, HF10, More, Nevro, Nevrocloud, Surpass and the Nevro, HF10, and Frequency Pairing Logos are trademarks of Nevro Corp.